company background image
EBO

EBOS GroupNZSE:EBO Stock Report

Market Cap

NZ$5.9b

7D

-0.03%

1Y

44.4%

Updated

04 Dec, 2021

Data

Company Financials +
EBO fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance4/6
Financial Health6/6
Dividends4/6

EBO Stock Overview

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand.

EBOS Group Competitors

Australian Pharmaceutical Industries

ASX:API

AU$862.1m

Sigma Healthcare

ASX:SIG

AU$519.1m

Price History & Performance

Summary of all time highs, changes and price drops for EBOS Group
Historical stock prices
Current Share PriceNZ$36.09
52 Week HighNZ$37.05
52 Week LowNZ$24.95
Beta0.31
1 Month Change1.83%
3 Month Change2.67%
1 Year Change44.36%
3 Year Change72.51%
5 Year Change120.06%
Change since IPO1,490.33%

Recent News & Updates

Oct 31
EBOS Group (NZSE:EBO) Has Some Way To Go To Become A Multi-Bagger

EBOS Group (NZSE:EBO) Has Some Way To Go To Become A Multi-Bagger

There are a few key trends to look for if we want to identify the next multi-bagger. Ideally, a business will show two...

Oct 18
An Intrinsic Calculation For EBOS Group Limited (NZSE:EBO) Suggests It's 23% Undervalued

An Intrinsic Calculation For EBOS Group Limited (NZSE:EBO) Suggests It's 23% Undervalued

Does the October share price for EBOS Group Limited ( NZSE:EBO ) reflect what it's really worth? Today, we will...

Sep 19
Is EBOS Group (NZSE:EBO) A Risky Investment?

Is EBOS Group (NZSE:EBO) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...

Shareholder Returns

EBONZ HealthcareNZ Market
7D-0.03%-0.01%0.4%
1Y44.4%8.4%-3.2%

Return vs Industry: EBO exceeded the NZ Healthcare industry which returned 8.4% over the past year.

Return vs Market: EBO exceeded the NZ Market which returned -3.2% over the past year.

Price Volatility

Is EBO's price volatile compared to industry and market?
EBO volatility
EBO Average Weekly Movement2.3%
Healthcare Industry Average Movement3.2%
Market Average Movement3.6%
10% most volatile stocks in NZ Market6.7%
10% least volatile stocks in NZ Market2.4%

Stable Share Price: EBO is less volatile than 75% of NZ stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: EBO's weekly volatility (2%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19223,105John Cullityhttps://www.ebosgroup.com

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand. It operates in two segments, Healthcare and Animal Care. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services.

EBOS Group Fundamentals Summary

How do EBOS Group's earnings and revenue compare to its market cap?
EBO fundamental statistics
Market CapAU$5.70b
Earnings (TTM)AU$185.30m
Revenue (TTM)AU$9.20b

30.8x

P/E Ratio

0.6x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EBO income statement (TTM)
RevenueAU$9.20b
Cost of RevenueAU$8.22b
Gross ProfitAU$984.31m
ExpensesAU$799.02m
EarningsAU$185.30m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)1.13
Gross Margin10.70%
Net Profit Margin2.01%
Debt/Equity Ratio31.7%

How did EBO perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

73%

Payout Ratio

Valuation

Is EBOS Group undervalued compared to its fair value and its price relative to the market?

22.7%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: EBO (NZ$36.09) is trading below our estimate of fair value (NZ$46.7)

Significantly Below Fair Value: EBO is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: EBO is poor value based on its PE Ratio (30.8x) compared to the Oceanic Healthcare industry average (24.8x).

PE vs Market: EBO is poor value based on its PE Ratio (30.8x) compared to the NZ market (19.9x).


Price to Earnings Growth Ratio

PEG Ratio: EBO is poor value based on its PEG Ratio (3.6x)


Price to Book Ratio

PB vs Industry: EBO is overvalued based on its PB Ratio (4x) compared to the XO Healthcare industry average (2.6x).


Future Growth

How is EBOS Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

8.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: EBO's forecast earnings growth (8.4% per year) is above the savings rate (2.1%).

Earnings vs Market: EBO's earnings (8.4% per year) are forecast to grow faster than the NZ market (7.2% per year).

High Growth Earnings: EBO's earnings are forecast to grow, but not significantly.

Revenue vs Market: EBO's revenue (4.6% per year) is forecast to grow slower than the NZ market (4.9% per year).

High Growth Revenue: EBO's revenue (4.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: EBO's Return on Equity is forecast to be low in 3 years time (15.3%).


Past Performance

How has EBOS Group performed over the past 5 years?

8.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: EBO has high quality earnings.

Growing Profit Margin: EBO's current net profit margins (2%) are higher than last year (1.9%).


Past Earnings Growth Analysis

Earnings Trend: EBO's earnings have grown by 8.5% per year over the past 5 years.

Accelerating Growth: EBO's earnings growth over the past year (14%) exceeds its 5-year average (8.5% per year).

Earnings vs Industry: EBO earnings growth over the past year (14%) underperformed the Healthcare industry 70.4%.


Return on Equity

High ROE: EBO's Return on Equity (13.1%) is considered low.


Financial Health

How is EBOS Group's financial position?


Financial Position Analysis

Short Term Liabilities: EBO's short term assets (A$2.1B) exceed its short term liabilities (A$1.9B).

Long Term Liabilities: EBO's short term assets (A$2.1B) exceed its long term liabilities (A$666.1M).


Debt to Equity History and Analysis

Debt Level: EBO's net debt to equity ratio (19.7%) is considered satisfactory.

Reducing Debt: EBO's debt to equity ratio has reduced from 34.6% to 31.7% over the past 5 years.

Debt Coverage: EBO's debt is well covered by operating cash flow (66.8%).

Interest Coverage: EBO's interest payments on its debt are well covered by EBIT (10.4x coverage).


Balance Sheet


Dividend

What is EBOS Group current dividend yield, its reliability and sustainability?

2.37%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: EBO's dividend (2.37%) isn’t notable compared to the bottom 25% of dividend payers in the NZ market (2.78%).

High Dividend: EBO's dividend (2.37%) is low compared to the top 25% of dividend payers in the NZ market (4.99%).


Stability and Growth of Payments

Stable Dividend: EBO's dividends per share have been stable in the past 10 years.

Growing Dividend: EBO's dividend payments have increased over the past 10 years.


Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (72.7%), EBO's dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: EBO's dividends in 3 years are forecast to be covered by earnings (70.6% payout ratio).


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

John Cullity

3.67yrs

Tenure

AU$3,700,000

Compensation

Mr. John Cullity has been Non-Executive Director of Terry White Group Limited since March 29, 2018. Mr. Cullity has been Chief Executive Officer of EBOS Group Limited since April 1, 2018. Mr. Cullity serve...


CEO Compensation Analysis

Compensation vs Market: John's total compensation ($USD2.60M) is above average for companies of similar size in the NZ market ($USD1.69M).

Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: EBO's management team is considered experienced (3.8 years average tenure).


Board Members

Experienced Board: EBO's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

EBOS Group Limited's employee growth, exchange listings and data sources


Key Information

  • Name: EBOS Group Limited
  • Ticker: EBO
  • Exchange: NZSE
  • Founded: 1922
  • Industry: Health Care Distributors
  • Sector: Healthcare
  • Market Cap: NZ$5.925b
  • Shares outstanding: 164.19m
  • Website: https://www.ebosgroup.com

Number of Employees


Location

  • EBOS Group Limited
  • 737 Bourke Street
  • Level 7
  • Docklands
  • Victoria
  • 3008
  • Australia

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/12/04 06:01
End of Day Share Price2021/12/03 00:00
Earnings2021/06/30
Annual Earnings2021/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.